[Intracellular targets : current data on effectiveness and safety profile]. - Wikidata - awgldk - TriplyDB

[Intracellular targets : current data on effectiveness and safety profile].

[Intracellular targets : current data on effectiveness and safety profile].

http://www.wikidata.org/entity/Q30689247

about

p38 MAPK inhibitors: a patent review (2012 - 2013).[New drugs in rheumatology].

P2860

Q38194600-41AEB106-8212-4045-B7A9-11B1D7415FA4 Q54374459-D626C1BB-0B7F-4699-A1EC-B1385832D46A

P2860

[Intracellular targets : current data on effectiveness and safety profile].

http://www.wikidata.org/entity/Q30689247

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

[Intracellular targets : current data on effectiveness and safety profile].

@ast

[Intracellular targets : current data on effectiveness and safety profile].

@en

type

label

[Intracellular targets : current data on effectiveness and safety profile].

@ast

[Intracellular targets : current data on effectiveness and safety profile].

@en

prefLabel

[Intracellular targets : current data on effectiveness and safety profile].

@ast

[Intracellular targets : current data on effectiveness and safety profile].

@en

P1433

Q30689247-F55DD8CE-681E-4919-AD37-7080C67F736E

P1476

Q30689247-27E6DE9E-72AE-4E3E-82F8-9C17223EB0D9

P2093

Q30689247-2D8BE131-5C8B-4779-9C64-E80F52EE16DC

P2860

Q30689247-0222CCD6-E42E-4A2E-8E7F-EE274FFBC5B3

Q30689247-0563B33B-0445-4035-BC58-16761B608213

Q30689247-1D8E9F54-78B2-47BA-8757-33DEC3ED0B75

Q30689247-2E084749-E495-48EF-BE3D-76D8F94CA61B

Q30689247-2EC43EBE-C31B-4C86-81B9-1DC04081FC6B

Q30689247-32261EEE-37A2-4207-A87D-FF4C37F98A0C

Q30689247-3BE26D35-4EDB-4760-ACFD-9CDFFDE58675

Q30689247-61332135-8D9D-4757-BA8B-897955328A3A

Q30689247-836A6CB4-1004-44E1-B3E6-0A343BA215D9

Q30689247-89BEE95D-BE09-4EF8-A5BB-84DB4C4A6948

P2888

Q30689247-6F9F1727-24D0-4D07-B2D9-ADE4A4876485

P304

Q30689247-E6E3C031-F2B0-42B5-ACB2-76CA5CE9A22B

P31

Q30689247-064C75CE-1C6C-4F53-83A9-1838842FD3E3

P356

Q30689247-181485BC-DD5B-4B24-ABAE-8FDB79692699

P407

Q30689247-49832E66-BFD2-4357-862B-20B0B164BAF6

P433

Q30689247-A0F65D45-380B-43D3-8E66-34F364D72559

P478

Q30689247-34E13538-79FF-40D4-B56F-10D610517C59

P577

Q30689247-402D2FDC-E123-404C-BF1E-72A811C00848

P6179

Q30689247-E476221E-58DC-4006-95A9-E1F4189FF190

P698

Q30689247-A15E029B-A3D4-4AE5-8CFD-780D380EC9CD

P356

S00393-013-1139-4

P1433

Zeitschrift fuer Rheumatologie

P1476

[Intracellular targets : current data on effectiveness and safety profile].

@en

P2093

R Alten

http://www.w3.org/2001/XMLSchema#string

P2860

Janus kinase inhibitors in autoimmune diseases

Jaks and STATs: biological implications

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Back to the future: oral targeted therapy for RA and other autoimmune diseases.

JAKs and STATs in immunity, immunodeficiency, and cancer.

Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Kinase inhibitors: a new class of antirheumatic drugs

P2888

s00393-013-1139-4

P304

867-872

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00393-013-1139-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050390104

http://www.w3.org/2001/XMLSchema#string

P698

24193189

http://www.w3.org/2001/XMLSchema#string